Introduction of 65 kDa Antigen of Mycobacterium tuberculosis to Cancer Cells Enhances Anti-Tumor Effect of BCG Therapy

Microbiology and Immunology

Volumn 48, Issue 4, 2004, Pages 289-295

  Hara, Isao ^a   Sato, Noriyuki ^b   Miyake, Hideaki ^c   Muramaki, Mototsugu ^a   Hikosaka, Satoko ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

Author keywords

65 kDa antigen; BCG; Gene therapy

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; HEAT SHOCK PROTEIN; LIPOFECTAMINE; MONOCLONAL ANTIBODY;

ACTINOBACTERIA; ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; BCG VACCINATION; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EXPRESSION VECTOR; GENETIC TRANSDUCTION; MELANOMA CELL; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; WESTERN BLOTTING;

ACTINOBACTERIA (CLASS); ANIMALIA; BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE; VECTORS;

EID: 1942485950     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2004.tb03525.x     Document Type: Article

References (28)

1. Gaston, J.S., Life, P.F., Jenner, P.J., Colston, M.J., and Bacon, P.A. 1990. Recognition of a mycobacteria-specific epitope in the 65-kD heat-shock protein by synovial fluid-derived T cell clones. J. Exp. Med. 171: 831-841.
2. Gillis, T.P., Miller, R.A., Young, D.B., Khanolkar, S.R., and Buchanan, T.M. 1985. Immunochemical characterization of a protein associated with Mycobacterium leprae cell wall. Infect. Immun. 49: 371-377.
3. Hara, I., Hotta, H., Sato, N., Eto, H., Arakawa, S., and Kamidono, S. 1996. Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2. Jpn. J. Cancer Res. 87: 724-729.
4. Hara, I., Nagai, H., Miyake, H., Yamanaka, K., Hara, S., Micallef, M.J., Kurimoto, M., Gohji, K., Arakawa, S., Ichihashi, M., and Kamidono, S. 2000. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther. 7: 83-90.
5. Hara, I., Nguyen, H., Takechi, Y., Gansbacher, B., Chapman, P.B., and Houghton, A.N. 1995. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int. J. Cancer 61: 253-260.
6. Hara, I., Sato, N., Kikuchi, K., and Kamidono, S. 1991. Immune response against BCG 65 kDa protein antigen in bladder cancer with BCG instillation therapy. Analyses carried out with the gene of this protein to develop a monoclonal antibody. Nippon Hinyokika Gakkai Zasshi 82: 24-32 (in Japanese).
7. Hara, I., Sato, N., Matsuura, A., Cho, J.M., Qi, W.M., Torigoe, T., Shinnick, T.M., Kamidono, S., and Kikuchi, K. 1991. Development of monoclonal antibodies reacting against mycobacterial 65 kDa heat shock protein by using recombinant truncated products. Microbiol. Immunol. 35: 995-1007.
8. Hara, S., Nagai, H., Miyake, H., Yamanaka, K., Arakawa, S., Ichihashi, M., Kamidono, S., and Hara, I. 2001. Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity. J. Urol. 165: 2039-2043.
9. Herr, H.W., and Sogani, P.C. 2001. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J. Urol. 166: 1296-1299.
10. Horiguchi, Y., Larchian, W.A., Kaplinsky, R., Fair, W.R., and Heston, W.D. 2000. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther. 7: 844-851.
11. Hurle, R., Losa, A., Manzetti, A., and Lembo, A. 1999. Intravesical bacille Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54: 258-263.
12. Kuball, J., Wen, S.F., Leissner, J., Atkins, D., Meinhardt, P., Quijano, E., Engler, H., Hutchins, B., Maneval, D.C., Grace, M.J., Fritz, M.A., Storkel, S., Thuroff, J.W., Huber, C., and Schuler, M. 2002. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J. Clin. Oncol. 20: 957-965.
13. Kuromatsu, I., Matsuo, K., Takamura, S., Kim, G., Takebe, Y., Kawamura, J., and Yasutomi, Y. 2001. Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an alpha antigen from mycobacteria. Cancer Gene Ther. 8: 483-490.
14. Lukacs, K.V., Lowrie, D.B., Stokes, R.W., and Colston, M.J. 1993. Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors. J. Exp. Med. 178: 343-348.
15. Lukacs, K.V., Nakakes, A., Atkins, C.J., Lowrie, D.B., and Colston, M.J. 1997. In vivo gene therapy of malignant tumours with heat shock protein-65 gene. Gene Ther. 4: 346-350.
16. Miller, J., and Germain, R.N. 1986. Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. J. Exp. Med. 164: 1478-1489.
17. Nagai, H., Hara, I., Horikawa, T., Fujii, M., Kurimoto, M., Kamidono, S., and Ichihashi, M. 2000. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest. 18: 206-213.
18. Nagai, H., Hara, I., Horikawa, T., Oka, M., Kamidono, S., and Ichihashi, M. 2000. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J. Invest. Dermatol. 115: 1059-1064.
19. Pagliaro, L.C., Keyhani, A., Williams, D., Woods, D., Liu, B., Perrotte, P., Slaton, J.W., Merritt, J.A., Grossman, H.B., and Dinney, C.P. 2003. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J. Clin. Oncol. 21: 2247-2253.
20. Shimizu, H., Akasaka, S., Suzuki, S., Akimoto, M., and Shimada, T. 2001. Preferential gene transfer to BBN-induced rat bladder tumor by simple instillation of adenoviral vector. Urology 57: 579-584.
21. Shinnick, T.M. 1987. The 65-kilodalton antigen of Mycobacterium tuberculosis. J. Bacteriol. 169: 1080-1088.
22. Shinnick, T.M., Vodkin, M.H., and Williams, J.C. 1988. The Mycobacterium tuberculosis 65-kilodalton antigen is a heat shock protein which corresponds to common antigen and to the Escherichia coli GroEL protein. Infect. Immun. 56: 446-451.
23. Shinomiya, Y., Harada, M., Kurosawa, S., Okamoto, T., Terao, H., Matsuzaki, G., Shirakusa, T., and Nomoto, K. 1995. Anti-metastatic activity induced by the in vivo activation of purified protein derivative (PPD)-recognizing Th1 type CD4+ T cells. Immunobiology 193: 439-455.
24. Southern, P.J., and Berg, P. 1982. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J. Mol. Appl. Genet. 1: 327-341.
25. Talic, R.F., Hargreave, T.B., Bishop, M.C., Kirk, D., and Prescott, S. 1994. Intravesical Evans bacille Calmette-Guerin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group. Br. J. Urol. 73: 645-648.
26. van Eden, W., Thole, J.E., van der Zee, R., Noordzij, A., van Embden, J.D., Hensen, E.J., and Cohen, I.R. 1988. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 331: 171-173.
27. Yamanaka, K., Hara, I., Nagai, H., Miyake, H., Gohji, K., Micallef, M.J., Kurimoto, M., Arakawa, S., and Kamidono, S. 1999. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol. Immunother. 48: 297-302.
28. Young, R.A., Mehra, V., Sweetser, D., Buchanan, T., Clark-Curtiss, J., Davis, R.W., and Bloom, B.R. 1985. Genes for the major protein antigens of the leprosy parasite Mycobacterium leprae. Nature 316: 450-452.